Background. The aromatase gene (CYP19A1) is responsible for the aromatization of androgenic precursors to estrogens in peripheral tissues -including bone -after menopause.
Introduction
Osteoporosis is a common disease in postmenopausal women and is characterized by reduced bone mass resulting in an increased risk of fractures. Furthermore, it has been demonstrated that bone mass is highly dependent on genetic and environmental factors. 1 Sex steroid hormones also have an important influence on bone mass. 2 The main source of estrogens in women after menopause is the aromatization of androgenic precursors. The conversion of androgens to estrogens is catalyzed in a variety of tissues and aromatase (CYP19A1) is the key enzyme in this transformation. 3, 4 It is known that the loss of bone mass occurs due to the age-related loss of gonadal function. The CYP19A1 gene is located on 15q21.2 and contains 10 exons; exons 2 to 10 are transcribed and translated to create the aromatase enzyme. [5] [6] [7] [8] Importantly, it has been demonstrated that the various polymorphisms in the CYP19A1 gene may positively or negatively correlate with aromatase activity, sex hormone levels, bone mineral density (BMD) values, and fractures. [9] [10] [11] [12] [13] [14] Therefore, polymorphisms of genes regulating hormone production and metabolism may potentially explain the etiology of osteoporosis. The aim of this study was to examine the potential effects of the rs749292 and rs700518 polymorphisms in the CYP19A1 gene on osteoporosis in postmenopausal women. To our knowledge, there are no studies on the relationship between the CYP19A1 rs749292 polymorphism and osteoporosis development in postmenopausal women.
Material and methods

Patients
The study was comprised of 675 unrelated Polish women, including 109 women with osteopenia, 333 women with osteoporosis, and 233 healthy women. All of the women were in a postmenopausal age. During an interview with each patient, data on the occurrence of diseases, the age of first and last menstruation, the number of pregnancies, birth weight, and current height and weight were collected. Then, the body mass index (BMI) was calculated for each patient. The inclusion criteria for genetic research included the following: the onset of menopause at least 1 year prior to the study and the lack of hormone replacement therapy (HRT) or medications that affect bone mass -such as selective estrogen receptor modulators (SERMs), calcitonin, biphosphates, heparin, steroids, thyroid hormones, antiepileptics, GnRH analogues, or tibolone. Patients with diseases which influence bone metabolism -such as endocrine and metabolic disorders, hematological diseases, cancer, connective tissue diseases, and autoimmune disorders -were excluded from the study. Additionally, the postmenopausal patients did not suffer from hypoestrogenism at reproductive age or the premenopausal period. This study also disqualified patients who had undergone bilateral ovariectomy and patients with premature ovarian insufficiency (POI). Moreover, vitamin D and calcium intake either in the diet or as a supplement was advised per current clinical practice, but their use was not recorded among the patients studied.
The BMD measurements were performed at the Laboratory of Densitometry in Clinical Hospital No. 1 of the Pomeranian Medical University in Szczecin, Poland. Bone mineral density was measured at the lumbar vertebrae and the femoral neck using the dual-energy x-ray absorptiometry method (DEXA) and a LUNAR DPX 100 densitometer (Lunar Corp., Madison, USA). All subjects underwent DEXA screening of lumbar vertebrae 2 to 4 (L2-L4). Bone mineral density values are presented as T-scores and Z-scores. Based on these measurements, the women were classified into 3 groups: those with osteopenia (−2.5< T-score <−1), those with osteoporosis (T-score <−2.5) and those with a normal T-score (T-score >−1).
Among the patients studied, we did not observe the occurrence of any fractures, though -based on the BMD and bone turnover values in some patients -there was a risk of fracture. In addition, serum estradiol levels were not measured in the patients because the study assumed that postmenopausal patients with osteoporosis would have decreased levels of estrogen. The characteristics of the study population (postmenopausal women with osteopenia, osteoporosis or normal T-scores) are presented in Table 1 .
The study was approved by the Local Bioethical Committee of the Pomeranian Medical University in Szczecin, Poland. All patients were informed about the purpose of the study and provided written informed consent.
Analysis of CYP19A1 polymorphisms
Blood samples were collected in the Department of Orthopedics and Traumatology at the Pomeranian Medical University. The analysis of CYP19A1 gene polymorphisms was conducted at the Department of Stem Cell and Regenerative Medicine at the Institute of Natural Fibers and Medicinal Plants in Poznań, Poland. Genomic DNA was extracted from peripheral blood using a QIAamp Blood Kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions.
CYP19A1 rs749292 (A>G, TaqI) and rs700518 (G>A, RsaI) variants were determined by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). The following primers were used for PCR: CYP19A1TaqIF: 5'-GCC ACC TGT CTC TCA TTC CA-3', CYP19A1TaqIR: 5-CTC CGT GAT TTG TCA GCT CTT-3' (386 bp), CYP-19A1RsaIF: 5'-AGT AAC ACA GAA CAG TTG CA-3', and CYP19A1RsaIR: 5'-TCC AGA CTC GCA TGA ATT CTC CGT A-3' (188 bp). The polymorphic sites were defined using restriction enzymes for the CYP19A1 gene, such as TaqI (AA: 327 bp, 59 bp; GG: 172bp, 155 bp, 59 bp) and RsaI (GG: 164 bp, 24 bp; AA: 188 bp). The PCR-RFLP products were separated by electrophoresis according to their size in 3% agarose gel with ethidium bromide and viewed under UV light.
Statistical analysis
Data analysis was performed using SPSS Statistics v. 17.0 software (SPSS Inc., Chicago, USA). The results are presented as mean values. The odds ratios (OR) are given with the respective 95% confidence intervals (95% CI). The observed frequencies were compared with the expected frequencies and tested for Hardy-Weinberg equilibrium. The distribution of variables was evaluated with the Shapiro-Wilk test. The homogeneity of variances was assessed using the Levene test. Quantitative variables were compared with one-way analysis of variances (ANOVA) with post hoc contrast comparison tests. Ordinal data were compared with a χ 2 test.
Results
Our analysis of the CYP19A1 rs749292 polymorphism showed that there were no statistically significant differences in the distribution of genotypes between women with osteoporosis or osteopenia and the control group (p = 0.109). However, it is noticeable that the mutant GG genotype occurred more often in the group with osteopenia (35.8%; OR = 1.44) than in the control group (27.9%). Also, a difference was observed in the distribution of genotypes among the women with osteoporosis. Despite a lack of statistical significance between the groups, the wild homozygote (AA) occurred more frequently among the control group (23.2%) than among the patients with osteopenia (21.1%) or those with osteoporosis (17.7%) ( Table 2) . There was only 1 statistically significant difference among the clinical parameters -the correlation between BMI and genotype in the osteopenia group (p = 0.049) -although this was not observed in the patients with osteoporosis. On the basis of these results, it can be assumed that the G allele (mutant) may lead to an increased susceptibility to osteopenia and osteoporosis. In our analysis of the CYP19A1 rs700518 polymorphism, there were no statistically significant differences in the distribution of genotypes between the groups with osteoporosis and osteopenia and the control group (p = 0.520). It was observed that heterozygotes were more common among the women with osteoporosis (58.3%) than in the control group (52.8%), but the difference was not statistically significant (Table 3 ). There were some statistically significant differences between clinical parameters and genotypes. Correlations were observed between genotype and BMI (p = 0.049), age (p = 0.035), and years after menopause (p = 0.012) in the patients with osteopenia. Osteopenia occurred at an earlier age (49.9 years) in the patients with the mutant AA genotype than in those with the GG (53.1 years) and GA (54.9 years) genotypes (p = 0.035). Also, a statistically significant difference was observed between genotype and age-matched bone mineral density (BMD-AM) (p = 0.042). The lowest BMD-AM was observed in patients with the recessive AA genotype. The BMD-AM values were higher among the women with the GG and GA genotypes. These results indicate a trend of a higher probability of osteopenia in the recessive homozygotes.
There were no statistically significant differences in genotype frequency among patients with osteoporosis, but a correlation did appear between the genotype and reproductive years (p = 0.042). 
Discussion
In this study, we observed no statistically significant effects of CYP19A1 polymorphisms on the occurrence of osteopenia and osteoporosis. No differences were noted in the distribution of the CYP19A1 rs749292 genotype between patients and controls. However, the GG genotype occurred more often in women with osteopenia than in the control group. Available studies indicate that genetic variations of the CYP19A1 gene, including rs749292, are associated with hormone levels in postmenopausal women with breast cancer. 15, 16 At the same time, while no data is available (according to our knowledge and literature review) on the allele and genotype frequencies for CYP19A1 rs749292 in postmenopausal women with osteopenia/osteoporosis compared to controls, results similar to ours were obtained by Yilmaz et al. 17 The authors of that study investigated the frequencies of the CYP19A1 rs700518 polymorphism in patients with osteoporosis and a control group from the Turkish population. They did not observe a relationship between the studied polymorphism and the occurrence of osteoporosis, though they did report a higher occurrence of the AG genotype (63%) among the control group. This relationship could have resulted from the limited size of the study group. They also pointed out the lower frequency of AA and AG genotypes among the patients. In our study, the AA genotype also occurred less frequently in osteoporotic patients (16.8%) compared with the control group (19.3%). However, the differences were not statistically significant (OR = 0.84; 95% CI = 0.53-1.34; p = 0.25).
Furthermore, Geng et al. found no significant effect of the rs700518 polymorphism on BMD in the Chinese population among postmenopausal women. 18 Similarly, in our study the GA genotype (44.5%) occurred most frequently, while the homozygous GG and AA genotypes accounted for 19.5% and 36%, respectively. The CYP19A1 rs700518 polymorphism was also reported to be associated with differences in BMD and hormone levels in men (n = 1068). Lorentzon et al. showed that men with the GG genotype had higher BMD values than carriers of the AG and AA genotypes. 1 Similar statistically significant results (p = 0.010) were obtained by Riancho et al. 11 Total hip BMD was the highest in patients with the GG genotype (0.823 g/cm 3 ) and was accordingly lower in those with the GA (0.807 g/cm 3 ) and AA (0.795 g/cm 3 ) genotypes.
In our study, we also observed the same relationship between genotype and AM-BMD values (p = 0.042) among female patients with osteopenia (89.3 for GG, 91.9 for GA and 78.9 for AA). Napoli et al. 14 conducted a study on women taking the aromatase inhibitor during breast cancer therapy and showed that patients with the AA genotype developed significant bone loss relative to patients carrying the G allele (GA and GG genotypes). These findings may suggest that the A allele leads to more susceptibility to bone loss during therapy and that the GG genotype has a protective influence.
Conclusions
Our results suggest that the rs749292 polymorphism of the CYP19A1 gene may contribute to an elevated risk for fractures in Polish postmenopausal women.
